Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Moleculin Biotech (MBRX) EBITDA (2016 - 2025)

Moleculin Biotech (MBRX) has 10 years of EBITDA data on record, last reported at -$35.0 million in Q3 2025.

  • For Q3 2025, EBITDA fell 399.89% year-over-year to -$35.0 million; the TTM value through Sep 2025 reached -$54.6 million, down 105.49%, while the annual FY2024 figure was -$21.8 million, 26.84% up from the prior year.
  • EBITDA reached -$35.0 million in Q3 2025 per MBRX's latest filing, down from -$7.6 million in the prior quarter.
  • Across five years, EBITDA topped out at -$2.8 million in Q4 2021 and bottomed at -$35.0 million in Q3 2025.
  • Average EBITDA over 5 years is -$7.7 million, with a median of -$6.4 million recorded in 2025.
  • Peak YoY movement for EBITDA: surged 57.87% in 2021, then plummeted 399.89% in 2025.
  • A 5-year view of EBITDA shows it stood at -$2.8 million in 2021, then crashed by 139.41% to -$6.8 million in 2022, then crashed by 51.97% to -$10.3 million in 2023, then surged by 46.52% to -$5.5 million in 2024, then crashed by 537.71% to -$35.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$35.0 million in Q3 2025, -$7.6 million in Q2 2025, and -$6.4 million in Q1 2025.